In a clinical trial, weekly subcutaneous injection of efruxifermin (a long-acting Fc-FGF21 fusion protein) effectively reduced hepatic fat fraction in non-alcoholic steatohepatitis patients and was generally well tolerated.120. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.